A phase I study of Integrated-stress-response-modulator-HiberCell in solid tumors and haematological malignancies
Latest Information Update: 04 Jan 2022
At a glance
- Drugs Integrated stress response modulator-HiberCell (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 04 Jan 2022 New trial record